Evidence map›Paper›PMID 37730108›Full record

ArticleLife sciences2023

Disparities in cardio-oncology: Implication of angiogenesis, inflammation, and chemotherapy.

Carlos D Vera, Agustín Rodríguez López, Alex S Ewaneewane, Kasey Lewis, Sophia Parmisano, Gema Mondejar-Parreño, Chandan Upadhyaya, McKay Mullen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Carlos D VeraStanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA.
Agustín Rodríguez LópezStanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA; University of Puerto Rico Medical Science Campus, Rio Piedras, PR, USA.
Alex S EwaneewaneStanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA; Meharry Medical College, Nashville, TN, USA.
Kasey LewisStanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA; Lehigh University, Bethlehem, PA, USA.
Sophia ParmisanoStanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA; University of California San Diego, San Diego, CA, USA.
Gema Mondejar-ParreñoStanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA.
Chandan UpadhyayaXavier University School of Medicine, Woodbury, NY, USA.
McKay MullenStanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA. Electronic address: mmullen4@stanford.edu.
Stanford Medicine · USXavier University · US

Funding

Elucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCsR01HL130020 · NHLBI · STANFORD UNIVERSITY · PI Ronglih Liao, MARK MERCOLA · 2016 to 2026
$7.3M
Stanford Cardiovascular Summer Research Training Program for Medical StudentsT35HL160496 · NHLBI · STANFORD UNIVERSITY · PI America Facundo, Joseph C. Wu · 2022 to 2026
$574k
NHLBI NIH HHS R01 HL130020
6 · The paper itself

Abstract

Cancers and cardiovascular diseases are the top two causes of death in the United States. Over the past decades, novel therapies have slowed the cancer mortality rate, yet cardiac failures have risen due to the toxicity of cancer treatments. The mechanisms behind this relationship are poorly understood and it is crucial that we properly treat patients at risk of developing cardiac failure in response to cancer treatments. Currently, we rely on early-stage biomarkers of inflammation and angiogenesis to detect cardiotoxicity before it becomes irreversible. Identification of such biomarkers allows healthcare professionals to decrease the adverse effects of cancer therapies. Angiogenesis and inflammation have a systemic influence on the heart and vasculature following cancer therapy. In the field of cardio-oncology, there has been a recent emphasis on gender and racial disparities in cardiotoxicity and the impact of these disparities on disease outcomes, but there is a scarcity of data on how cardiotoxicity varies across diverse populations. Here, we will discuss how current markers of angiogenesis and inflammation induced by cancer therapy are related to disparities in cardiovascular health.

Indexed as

Antineoplastic AgentsHeart FailureNeoplasmsBiomarkersCardiotoxicityHumansInflammationAntineoplastic AgentsBiomarkerscancerCardio-oncologyCardiotoxicityCardiovascular diseaseDisparitiesHealthcare

Identifiers

PMID37730108
PMCPMC11554401
OpenAlexW4386827658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.